GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Cost of Goods Sold

Hoth Therapeutics (Hoth Therapeutics) Cost of Goods Sold : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Cost of Goods Sold?

Hoth Therapeutics's cost of goods sold for the three months ended in Mar. 2024 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hoth Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Hoth Therapeutics Cost of Goods Sold Historical Data

The historical data trend for Hoth Therapeutics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hoth Therapeutics Cost of Goods Sold Chart

Hoth Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
Get a 7-Day Free Trial - - - - -

Hoth Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hoth Therapeutics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hoth Therapeutics  (NAS:HOTH) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hoth Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Hoth Therapeutics's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Hoth Therapeutics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Hoth Therapeutics (Hoth Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Executives
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie director, officer: CEO and President C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns officer: Chief Scientific Officer 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes director 1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc 10 percent owner 725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr director C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner 10 percent owner 44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor 10 percent owner 750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern 10 percent owner 20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023

Hoth Therapeutics (Hoth Therapeutics) Headlines